Quest Journals
Journal of Research in Pharmaceutical Science
Volume 9 ~ Issue 9 (2023) pp: 01-06
ISSN(Online) : 2347-2995
www.questjournals.org

Research Paper

Role of Tamoxifen in Breast Cancer

Ms.Shrutika Thakare[1], Mr.Gaurav Mude[2], Dr. Sandeep Srivastava[3], Dr.Yuvraj Srinivasan[4]

1. *Clinical Research Department, School of Allied Health Sciences, DattaMeghe Institute of Higher Education and Research, Sawangi (Meghe), Wardha, Maharashtra, India. Pin Code: 442001*
2. *Departmentof Pharmacology, DattaMeghe College of Pharmacy, DattaMeghe Institute of Higher Education and Research, Sawangi (Meghe), Wardha, Maharashtra, India. Pin Code: 442001*
3. *Clinical Research Department, Acharya VinobaBhave Rural Hospital, Jawaharlal Nehru Medical College, DattaMeghe Institute of Higher Education and Research, Sawangi(Meghe), Wardha, Maharashtra, India. Pin Code: 442001*
4. *Clinical Research Department,Acharya VinobaBhave Rural Hospital,Jawaharlal Nehru medical college,DattaMeghe Institute of Higher Education and Research, Sawangi (Meghe), Wardha, Maharashtra, India. Pin Code: 442001*

***Corresponding Author:** Ms.Shrutika Thakare[1]*

1. *Clinical Research Department, School of Allied Health Sciences, DattaMeghe Institute of Higher Education and Research, Sawangi (Meghe), Wardha, Maharashtra, India. Pin Code: 442001*

Abstract

Breast cancer continues to be a substantial health burden around the world, demanding appropriate therapeutic options. Tamoxifen, a selective oestrogen receptor modulator, has been used to treat breast cancer for almost four decades. This study aims to offer a complete overview of the function of tamoxifen in both the prevention and treatment of breast cancer.

Tamoxifen has been widely utilised as adjuvant treatment, and its efficacy in preventing disease recurrence and enhancing disease-free survival in ER-positive breast cancer patients is well documented. Notably, its advantages have been shown to last for up to 15 years after diagnosis. Tamoxifen, on the other hand, has a limited effect on ER-negative cancers and may perhaps slightly increase their occurrence.

Tamoxifen's mode of action involves competing with oestrogen for binding to ER, thereby inhibiting estrogen-mediated breast tissue signalling and proliferation. Its complex cellular mechanisms also include apoptotic activity, modulation of cytokines and effects on hormonal control of malignant cell dynamics.

Tamoxifen has shown promise in preventing the breast cancer in high-risk women, reducing the risk by 30%-40%. Nevertheless, its clinical application endometrial cancer, blood clots, heat flushes, and hepatotoxicity are among the significant side effects.

In premenopausal women, tamoxifen is a valuable adjuvant treatment, and its combination with ovarian suppression/ablation enhances therapeutic outcomes. Postmenopausal women may also benefit from tamoxifen, which has agonist effects on the liver, bones, and human cardiovascular system, reducing total and LDL (Low density lipoprotein) cholesterol levels.

Despite its long-standing success, ongoing research is exploring the potential of tamoxifen in treating other types of cancer and conditions like osteoporosis. Understanding its agonist-antagonist action in certain tissues has led to insights into its complex mode of action.

In conclusion, tamoxifen remains a gold standard in treating ER-positive breast cancer and as a preventive agent in high-risk individuals.

Keywords

Breast cancer, Tamoxifen, ER-positive breast cancer, ER-negative breast cancer, Selective estrogen receptor modulator

***R**eceived 26 August, 2023; **R**evised 05 Sep., 2023; **A**ccepted 07 Sep., 2023 © The author(s) 2023.*
P**ublished with open access at **www.questjournals.org

I. Introduction

A projected 2.3 million new cases in 2020, it is presently surpassing cancer of lung as the leading cause of cancer incidence worldwide, making up 11.7% of all cancer cases. Breast cancer was responsible for 13.5 percent (178361) of the total number of cancer cases and ten percent (90408) of deaths in India, according to Globocan 2020 data, resulting in a total risk of 2.81. [(1)]

Patients with the cancer of breast have a lower survival rate in India than in foreign countries, owing to older age at commencement, late stage of sickness at manifestation, delayed initiation of ultimate leadership, and inadequate/fragmented treatment. [(2)]

In consonance with the World Health Organisation (WHO), Breast cancer strategies continue to be based on reducing breast cancer outcome and life through early detection. Breast cancer is treated with a variety of contemporary medications. Cancer of the breast can be avoided inpersons who are predisposed to it by taking antioestrogens like raloxifene or tamoxifen. [(3)]

Tamoxifen can lower the risk of breast cancer by 30%-40% in high-risk women; yet,tamoxifenhas medically serious adverse reactions and the overall harm-benefit ratio is unknown. Tamoxifen also only prevents ER-positive breast cancer while having little or no effect on ER-negative tumours or modestly increasing their occurrence. [(4)]



Fig : 1 Chemical structure of tamoxifen molecule

Structure of Tamoxifen: Tamoxifen [trans-1-(4-b-dimethylaminoethoxyphenyl)-1,2-diphenylbut-1-ene] is a drug that is used to treat breast cancer. (Fig. 1), used to treatcancer by displacing oestrogen, the natural ligand for the oestrogen receptor, and by prevention of receptor ligation with the co-activator to inhibit subsequent signalling and proliferation in breast tissue. It comes as a pill or an oral solution, and among of the most noticeable side effects include a partial agonist activity on endometrial tissue, which stimulates cell proliferation. and has been linked to endometrium cancer. Blood clots, hot flashes, irregular periods, cardiovascular and metabolic problems are also possible. as well as hepatotoxicity. According to a recent assessment, the likelihood of restrictions during nursing or pregnancy has been a major source of concern. [(5)]

Tamoxifen in Preventing Breast Cancer

Tamoxifen became the "gold standard," with no other competitors, establishing the concepts of tumour targeting and determining the optimum therapeutic strategy to enhance survivorship in breast cancer patients. [(6)] Tamoxifen, a 5-year anti-adhesion medication, increases disease-free life and lowers recurrences by 50% in ER-positive patients 15 years after diagnosis. In ER-negative breast cancer, adjuvant tamoxifen has no effect on disease-free or overall survival. Five years of adjuvant tamoxifen is beneficial in premenopausal women with ER. The benefits of tamoxifen in terms of breast cancer lives saved outweigh the risks of endometrial cancer in postmenopausal women. Tamoxifen has no effect on the occurrence of secondary malignancies other than endometrial cancer. Tamoxifen had no non-cancer-related overall survival advantage when taken as adjuvant therapy.As a result, translational research using tamoxifen targeting the ER with a fair duration of adjuvant therapy (5 years) is recommended in the treatment of breast cancer. has contributed to a drop in cancer-related deaths across the country. Tamoxifen, on the other hand, has been the subject of substantial research, which has found minor but significant adverse effects like as endometrial cancer, blood clots, and the development of developed resistance. A research of tamoxifen and related nonsteroidalantioestrogens (e.g., raloxifene) resulted in the laboratory detection of selective ER control and the translation of the concept of utilising raloxifene for

osteoporosis and breast cancer prevention. Tamoxifen and raloxifene are both SERMs that can inhibit estrogen-mediated breast cancer growth and progression in postmenopausal women while also maintaining bone mineral density and reducing circulating cholesterol, 1The section that follows will demonstrate their significant and ongoing worth. With the second SERM, raloxifene, which has been proved in some populations to be an effective breast cancer preventive medicine.[7]

Mechanism of action of Tamoxifen

Hormonal therapy has been demonstrated to be quite beneficial in both adjuvant and metastatic disease. This procedure is required for those with positive hormone receptor (ER) breast neoplasms. Tamoxifen is considered the most active adjuvant hormonal treatment in pre- and post-menopausal women who respond well to it since it is primarily dependent on ER and PR% in breast cancer cells.[8]Tamoxifen has a bone, the liver, and circulatory system agonist action, decreasing total and LDL cholesterol. [9]

It's having an antagonist impact in the uterus and breast cells, or a mixed effect depending on the species, target gene, and organ. [10]

Tamoxifen, for example, regulates estrogen-responsive gene signalling pathways in breast tissue by competing with oestrogen for receptor binding and blocking oestrogen via triggering the co-repressor nuclear receptor coreceptor, retinoid silencing mediator, and thyroid hormone recruiting to ER target gene. Tamoxifen activates the co-activator steroid receptor co-activator-1 [SRC-1] and CREP-binding protein to the ER target gene in endometrial cells rather than a co-repressor. These are performed by competing for the binding site with estradiol. Tamoxifen stimulates the binding of oestrogen to its receptors in bone cells, acting as an oestrogen agonist and preventing osteoporosis. especially in postmenopausal women Tamoxifen Mechanisms in cells are a complex process that consists of multiple distinct and well-defined processes. Tamoxifen, for example, impacts pathways of signalling in tissue from the breast that correspond to estrogen-responsive genes, where it competes with oestrogen for binding to its receptors, effectively suppressing oestrogen. Tamoxifen binds to the oestrogen receptor and inhibits the action of oestrogen on mammary epithelial tissues by affixing to cytoplasmic antiestrogenic receptors; increasing intracellular drug and sex hormones that bind to globulin, resulting in a decrease in free oestrogen that diffuses into tumour cells and induces their proliferation. As a result, it has the ability to modulate oestrogen receptors. Tamoxifen's anti-proliferation action could be related to an increase in cytokine transforming growth factors (TGF- and TGF-), It acts as an anti-autocrine regulating molecule Nonetheless, tamoxifen has been proven to cause breast cancer.[11]

Tamoxifen is hypothesised to trigger the production of the transforming growth factor B (TGF-B), meaning that it has both paracrine and autocrine activity. It also boosts natural killer cells while decreasing insulin-like growth factor, a cancer cell mitogen. Tamoxifen stimulates cancer cell growth through endocrine, paracrine, and autocrine pathways. It also has an impact on the hormonal regulation of malignant cell dynamics. [12]

Tamoxifen inhibits protein kinase C, which is thought to decrease DNA synthesis in oestrogen receptor-positive cells via inducing apoptosis. Another explanation for tamoxifen's apoptotic activity is that it is mediated by a threefold rise in calcium ion concentrations in the cell and mitochondria following TGF-B activation with tamoxifen or chemotherapy alone. However, several studies have found that this combination improves overall survival with more activity than tamoxifen or chemotherapy alone. [13]

Two additional trials, one examining the combination's efficacy in patients with node-negative breast cancer and ER-positive tumours and the other in postmenopausal patients with ER-negative (ER-), discovered that the combined group of patients had a lower rate of recurrence than the tamoxifen or chemotherapy groups, with no difference in overall survival. [14]



Fig : 2 Mechanism of action of tamoxifen

Oestrogen and Oestrogen Receptors

Historically, oestrogen action at target sites throughout the body is mediated by ER and ER, two related but distinct oestrogen receptors (ERs).[15] which then bind as dimers to estrogen-responsive elements in estrogen-responsive gene regulatory regions and communicate with basal transcription variables, coactivators, and corepressors to regulate gene expression [16] Despite recent evidence to the contrary, the discovery of specialised high-affinity oestrogen binding in non-nuclear subcellular fractions such as the plasma membrane and mitochondria suggests that the ER may be found in these locations. [17] The ER and ER have 96% amino-acid identity in their DNA binding domains but only 53% homology in their ligand-binding regions, which explains for differences in the two receptors' responses to different ligands. Tamoxifen (Nolvadex; AstraZeneca, Wilmington, DE, USA), for example, has been proven to be both an agonist and an antagonist for ER. [18]

The identification of specific to tissue agonist-antagonist activity in tamoxifen and other selective oestrogen receptor modulators (SERMs) revealed that the traditional model was faulty and that oestrogen action was more complex than previously thought. Though only partially understood, the mechanisms of tissue-specific, mixed agonist-antagonist action of SERMs are rapidly becoming clearer. [19] The discovery of tissue-specific agonist-antagonist activity in tamoxifen and other selective oestrogen receptor modulators (SERMs) demonstrated that the traditional paradigm was erroneous and that oestrogen action was more nuanced than previously thought. Although still poorly understood, the mechanisms of SERMs' tissue-selective, mixed agonist-antagonist activity are becoming apparent. [20]

Tamoxifen can reduce the risk of breast cancer in high-risk women by 30%-40%; however, tamoxifen has clinically significant side effects, and the overall risk-benefit ratio is uncertain. [21]Tamoxifen also definitely prevents only ER-positive breast cancer while having little effect on or slightly increasing the prevalence of ER-negative tumours. [22]

Tamoxifen in Premenopausal and Postmenopausal breast cancer women

Breast cancer remains the most common cancer in women in the United States, accounting for about 230,000 new cases and 40,000 deaths each year. [23] The vast majority of new cases (i.e., stages I-II) are in the early stages of the disease, with approximately one-quarter diagnosed in premenopausal women. Hormone-receptor positive (HR+) breast cancer is the most common subtype, and decades of clinical studies improving adjuvant endocrine therapy have resulted in significant improvements in outcomes. [24] Recent large-scale international trials have demonstrated that prolonged endocrine therapy and adjuvant ovarian suppression minimise breast cancer recurrence rates. [25] Despite these advances, determining the best endocrine therapy strategy for premenopausal early stage HR+ breast cancer remains difficult, given the favourable prognoses of many patients and the inherent risk of overtreatment, as well as the short- and long-term toxicities associated with such medications. [26] As adjuvant endocrine therapies for premenopausal women, tamoxifen with or without ovarian suppression (OS)/ovarian ablation (OA), an aromatase inhibitor (AI) with OS/OA, or OS/OA

alone are currently available. Endocrine therapy is only indicated for breast cancers that express the oestrogen receptor (ER), as determined by clinically approved techniques. [(27)]

Tamoxifen is a selective oestrogen receptor modulator (SERM) that can be used to treat breast cancer in both premenopausal and postmenopausal women. It lowers the risk of disease recurrence in early stages of breast cancer by roughly 40% and the risk of death by about thirty percent when taken for 5 years [(28)] Serum estradiol levels have no effect on its therapeutic efficacy. Because the goal of therapy is to reduce oestrogen receptor signalling, and the ovaries produce the vast majority of oestrogen in premenopausal women, ovarian ablation (OA) or ovarian suppression (OS), either alone or in combination with tamoxifen, is an alternative to tamoxifen alone. The most effective method of lowering circulating oestrogen levels is bilateral oophorectomy or radiation, both of which result in a permanent cessation of menstruation. Alternatively, luteinizing hormone-releasing hormone (LHRH) agonists such as triptorelin, goserelin, or leuprolide may reduce ovarian activity briefly. Because most clinical studies are conducted every 28 days (rather than every 84 days), these injectable or subcutaneous depot medicines should be administered every 28 days. Because trials used monthly delivery, there is concern that the medication's efficacy may wane before the end of the dosage cycle. [(29)] However, due to a lack of efficacy data, it is not recommended to utilise OS/OA as the sole therapy for breast cancer treatment unless the patient is unable or unable to receive treatment with another acceptable systemic medication. [(30)]Tamoxifen can also be replaced with an aromatase inhibitor (AI). AIs like as anastrozole and letrozole, as well as the steroidal drug exemestane, appear to be equally effective in postmenopausal women with early stage breast cancer similarly efficacious in postmenopausal women with early stage breast cancer. [(31)]and have been shown to be more effective than tamoxifen in postmenopausal women on many occasions. However, AI medications alone are useless in premenopausal women since they function peripherally by inhibiting testosterone conversion to oestrogen and have no effect in high oestrogen circumstances. [(32)] As a result, it is crucial to confirm menopausal status in any patient with HR+ breast cancer before considering endocrine therapy, and to combine therapy with OS/OA if treatment with an AI is desired in a woman who is not obviously postmenopausal. [(33)]Tamoxifen alone, OA/OS alone, or OA/OS in combination with either tamoxifen or an AI are the endocrine therapy options for a premenopausal woman. As discussed further below, deciding which premenopausal women should get endocrine therapy in conjunction with OS/OA is difficult due to efficacy and tolerability issues (see section Contemporary Trials of Ovarian Suppression). [(34)]

II. Conclusion

Tamoxifen is a well-established medication that has been used for over 40 years to prevent and treat breast cancer. It works as blocking the action of oestrogen on cells of breast, and has shown to be effective in both advanced and early stages of breast **cancer. been shown** to be effective in both early and advanced stages of breast cancer. Tamoxifen is also being investigated for its potential in treating other types of cancer, as well as other diseases such as osteoporosis. Although Tamoxifen can cause side effects, it is generally well-tolerated, and the benefits of treatment often outweigh the risks.

References

[1]. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: a cancer journal for clinicians. 2021 May;71(3):209-49.

[2]. Kulothungan V, Sathishkumar K, Leburu S, Ramamoorthy T, Stephen S, Basavarajappa D, Tomy N, Mohan R, Menon GR, Mathur P. Burden of cancers in India-estimates of cancer crude incidence, YLLs, YLDs and DALYs for 2021 and 2025 based on National Cancer Registry Program. BMC cancer. 2022 May 11;22(1):527.

[3]. Peng J, Sengupta S, Jordan VC. Potential of selective estrogen receptor modulators as treatments and preventives of breast cancer. Anti-Cancer Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry-Anti-Cancer Agents). 2009 Jun 1;9(5):481-99.

[4]. Cuzick J, Forbes J, Edwards R, Baum M, Cawthorn S, Coates A, et al. First results from the International Breast Cancer Intervention Study (IBIS-I): a randomised prevention trial. Lancet 2002;360:817–24.

[5]. Schuurman TN, Witteveen PO, Van der Wall E, Passier JL, Huitema AD, Amant F, Lok CA. Tamoxifen and pregnancy: an absolute contraindication?. Breast Cancer Research and Treatment. 2019 May 15;175:17-25.

[6]. Jensen EV, Jordan VC. The estrogen receptor: a model for molecular medicine. Clinical cancer research. 2003 Jun 1;9(6):1980-9.

[7]. Lewis-Wambi JS, Jordan VC. Treatment of postmenopausal breast cancer with selective estrogen receptor modulators (SERMs) Breast Dis. 2005; 24: 93–105. doi: 10.3233. BD-2006-24108.[Abstract][CrossRef][Google Scholar].

[8]. Swaby RF, Sharma CG, Jordan VC. SERMs for the treatment and prevention of breast cancer. Reviews in Endocrine and Metabolic Disorders. 2007 Sep;8:229-39.

[9]. Davies C, Pan H, Godwin J, Gray R, Arriagada R, Raina V, Abraham M, Alencar VH, Badran A, Bonfill X, Bradbury J. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. The Lancet. 2013 Mar 9;381(9869):805-16.

[10]. Hu R, Hilakivi-Clarke L, Clarke R. Molecular mechanisms of tamoxifen-associated endometrial cancer. Oncology letters. 2015 Apr 1;9(4):1495-501.

[11]. Musa MA, Khan OF, Cooperwood JS. Medicinal chemistry and emerging strategies applied to the development of selective estrogen receptor modulators (SERMs). Current medicinal chemistry. 2007 May 1;14(11):1249-61.

[12]. Radin DP, Patel P. Delineating the molecular mechanisms of tamoxifen'soncolytic actions in estrogen receptor-negative cancers. European journal of pharmacology. 2016 Jun 15;781:173-80.

[13]. Clifford RE, Bowden D, Blower E, Kirwan CC, Vimalachandran D. Does tamoxifen have a therapeutic role outside of breast cancer? A systematic review of the evidence. Surgical Oncology. 2020 Jun 1;33:100-7.

[14]. Gelber RD, Cole BF, Goldhirsch A, Rose C, Fisher B, Osborne CK, Boccardo F, Gray R, Gordon NH, Bengtsson NO, Sevelda P. Adjuvant chemotherapy plus tamoxifen compared with tamoxifen alone for postmenopausal breast cancer: meta-analysis of quality-adjusted survival. The Lancet. 1996 Apr 20;347(9008):1066-71.

[15]. Albain KS, Barlow WE, Ravdin PM, Farrar WB, Burton GV, Ketchel SJ, Cobau CD, Levine EG, Ingle JN, Pritchard KI, Lichter AS. Adjuvant chemotherapy and timing of tamoxifen in postmenopausal patients with endocrine-responsive, node-positive breast cancer: a phase 3, open-label, randomised controlled trial. The Lancet. 2009 Dec 19;374(9707):2055-63.

[16]. Early Breast Cancer Trialists' Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. The Lancet. 2005 May 14;365(9472):1687-717.

[17]. Couse JF, Korach KS. Estrogen receptor null mice: what have we learned and where will they lead us?. Endocrine reviews. 1999 Jun 1;20(3):358-417.

[18]. Enmark E, Gustafsson JÅ. Oestrogen receptors–an overview. Journal of internal medicine. 1999 Aug;246(2):133-8.

[19]. Wang PH. Role of sex hormone receptors in ovulation. Taiwanese Journal of Obstetrics and Gynecology. 2005 Mar 1;44(1):16-25.

[20]. Yager JD, Davidson NE. Estrogen carcinogenesis in breast cancer. New England Journal of Medicine. 2006 Jan 19;354(3):270-82.

[21]. McDonnell DP. The molecular pharmacology of SERMs. Trends in Endocrinology & Metabolism. 1999 Oct 1;10(8):301-11.

[22]. Fan P, Jordan VC. New insights into acquired endocrine resistance of breast cancer. Cancer drug resistance. 2019;2(2):198.

[23]. Riggs BL, Hartmann LC. Selective estrogen-receptor modulators—mechanisms of action and application to clinical practice. New England Journal of Medicine. 2003 Feb 13;348(7):618-29.

[24]. Hammond ME, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S, Fitzgibbons PL, Francis G, Goldstein NS, Hayes M, Hicks DG. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer (unabridged version). Archives of pathology & laboratory medicine. 2010 Jul 1;134(7):e48-72

[25]. Kiely B, Stockler M. Meta-analysis: adjuvant tamoxifen reduces recurrence and death at 15 years in ER-positive early breast cancer. Annals of Internal Medicine. 2012 Mar;156(12):JC3-4.

[26]. Basch EM, Somerfield MR, Beer TM, Carducci MA, Higano CS, Hussain MH, Scher HI. American Society of Clinical Oncology endorsement of the Cancer Care Ontario Practice Guideline on nonhormonal therapy for men with metastatic hormone-refractory (castration-resistant) prostate cancer. Journal of Clinical Oncology. 2007 Nov 20;25(33):5313-8.

[27]. Goss PE, Ingle JN, Pritchard KI, Ellis MJ, Sledge GW, Budd GT, Rabaglio M, Ansari RH, Johnson DB, Tozer R, D'Souza DP. Exemestane versus anastrozole in postmenopausal women with early breast cancer: NCIC CTG MA. 27—a randomized controlled phase III trial. Journal of clinical oncology. 2013 Apr 4;31(11):1398.

[28]. Dowsett M, Cuzick J, Ingle J, Coates A, Forbes J, Bliss J, Buyse M, Baum M, Buzdar A, Colleoni M, Coombes C. Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen. Journal of Clinical Oncology. 2010 Jan 20;28(3):509-18.

[29]. Lim S, Park SH, Park HK, Hur MH, Oh SJ, Suh YJ. Prognostic role of adjuvant chemotherapy in node-negative (N0), triple-negative (TN), medullary breast cancer (MBC) in the Korean population. PloS one. 2015 Nov 12;10(11):e0140208.

[30]. Guerrero A, Gavilá J, Folkerd E, Ortiz B, Martínez F, García A, Climent MA, Guillem V, Ruíz A. Incidence and predictors of ovarian function recovery (OFR) in breast cancer (BC) patients with chemotherapy-induced amenorrhea (CIA) who switched from tamoxifen to exemestane. Annals of oncology. 2013 Mar 1;24(3):674-9.

[31]. Henry NL, Xia R, Banerjee M, Gersch C, McConnell D, Giacherio D, Schott AF, Pearlman M, Stearns V, Partridge AH, Hayes DF. Predictors of recovery of ovarian function during aromatase inhibitor therapy. Annals of oncology. 2013 Aug 1;24(8):2011-6.

[32]. Chirgwin J, Sun Z, Smith I, Price KN, Thürlimann B, Ejlertsen B, Bonnefoi H, Regan MM, Goldhirsch A, Coates AS, BIG 1-98 Collaborative and International Breast Cancer Study Groups. The advantage of letrozole over tamoxifen in the BIG 1-98 trial is consistent in younger postmenopausal women and in those with chemotherapy-induced menopause. Breast cancer research and treatment. 2012 Jan;131:295-306.

[33]. Goss PE, Ingle JN, Martino S, Robert NJ, Muss HB, Livingston RB, Davidson NE, Perez EA, Chavarri-Guerra Y, Cameron DA, Pritchard KI. Impact of premenopausal status at breast cancer diagnosis in women entered on the placebo-controlled NCIC CTG MA17 trial of extended adjuvant letrozole. Annals of oncology. 2013 Feb 1;24(2):355-61.

[34]. Grunfeld EA, Hunter MS, Sikka P, Mittal S. Adherence beliefs among breast cancer patients taking tamoxifen. Patient education and counseling. 2005 Oct 1;59(1):97-102.